Cargando…

A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity

Chimeric antigen receptors (CARs) can redirect T cells against antigen-expressing tumors in an HLA-independent manner. To date, various CARs have been constructed using mouse single chain antibody variable fragments (scFvs) of high affinity that are immunogenic in humans and have the potential to me...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, De-Gang, Ye, Qunrui, Poussin, Mathilde, Liu, Lin, Figini, Mariangela, Powell, Daniel J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673284/ https://www.ncbi.nlm.nih.gov/pubmed/26101914

Ejemplares similares

Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level
por: Song, De-Gang, et al.
Publicado: (2016)

Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor
por: Schutsky, Keith, et al.
Publicado: (2015)

Multiparameter comparative analysis reveals differential impacts of various cytokines on CART cell phenotype and function ex vivo and in vivo
por: Xu, Xiao-Jun, et al.
Publicado: (2016)

Fully human CD19-specific chimeric antigen receptors for T-cell therapy
por: Sommermeyer, Daniel, et al.
Publicado: (2017)

Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing
por: Liu, Jie, et al.
Publicado: (2019)

Toxicity of Chimeric Antigen Receptor T Cells and its Management
por: Wudhikarn, Kitsada, et al.
Publicado: (2021)

Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains
por: Lam, Norris, et al.
Publicado: (2020)

A Functional Screening Strategy for Engineering Chimeric Antigen Receptors with Reduced On-Target, Off-Tumor Activation
por: Di Roberto, Raphaël B., et al.
Publicado: (2020)

Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies
por: Wang, Haobing, et al.
Publicado: (2023)

Molecular Characterization of a Fully Human Chimeric T-Cell Antigen Receptor for Tumor-Associated Antigen EpCAM
por: Shirasu, Naoto, et al.
Publicado: (2012)

A chimeric antigen receptor against prostate-specific membrane antigen, a tumor vasculature target
por: Santoro, Stephen P, et al.
Publicado: (2013)

Lym-1 Chimeric Antigen Receptor T Cells Exhibit Potent Anti-Tumor Effects against B-Cell Lymphoma
por: Zheng, Long, et al.
Publicado: (2017)

Corrigendum to “Molecular Characterization of a Fully Human Chimeric T-Cell Antigen Receptor for Tumor-Associated Antigen EpCAM”
por: Shirasu, Naoto, et al.
Publicado: (2015)

Author Correction: Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains
por: Lam, Norris, et al.
Publicado: (2020)

A lymphodepleted non‐human primate model for the assessment of acute on‐target and off‐tumor toxicity of human chimeric antigen receptor‐T cells
por: Yagyu, Shigeki, et al.
Publicado: (2021)

Thrombotic Events Are Unusual Toxicities of Chimeric Antigen Receptor T-Cell Therapies
por: Schorr, Christopher, et al.
Publicado: (2023)

Generation of Chimeric Antigen Receptors against Tetraspanin 7
por: Pieper, Tom, et al.
Publicado: (2023)

Humanized CD30-Targeted Chimeric Antigen Receptor T Cells Exhibit Potent Preclinical Activity Against Hodgkin’s Lymphoma Cells
por: Guo, Jing, et al.
Publicado: (2022)

Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity
por: Davenport, A. J., et al.
Publicado: (2018)

The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells
por: Gargett, Tessa, et al.
Publicado: (2014)

Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
por: Yu, Shengnan, et al.
Publicado: (2019)

The Influence of Chimeric Antigen Receptor Structural Domains on Clinical Outcomes and Associated Toxicities
por: Davey, Ashleigh S., et al.
Publicado: (2020)

Inefficient exploitation of accessory receptors reduces the sensitivity of chimeric antigen receptors
por: Burton, Jake, et al.
Publicado: (2023)

Finding a needle in a haystack: Activation-induced CD137 expression accurately identifies naturally occurring tumor-reactive T cells in cancer patients
por: Ye, Qunrui, et al.
Publicado: (2013)

Current and future perspectives of chimeric antigen receptors against glioblastoma
por: Zhang, Josephine, et al.
Publicado: (2022)

Engineering Chimeric Antigen Receptors
por: Kulemzin, S. V., et al.
Publicado: (2017)

Conditionally Replicating Vectors Mobilize Chimeric Antigen Receptors against HIV
por: Urak, Ryan Z., et al.
Publicado: (2020)

Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma
por: Brammer, Jonathan E, et al.
Publicado: (2021)

Engineering chimeric antigen receptor-T cells for cancer treatment
por: Ye, Baixin, et al.
Publicado: (2018)

Chimeric antigen receptors that trigger phagocytosis
por: Morrissey, Meghan A, et al.
Publicado: (2018)

Chimeric Antigen Receptors for T-Cell Malignancies
por: Scherer, Lauren D., et al.
Publicado: (2019)

Engineering and Design of Chimeric Antigen Receptors
por: Guedan, Sonia, et al.
Publicado: (2018)

The Chimeric Antigen Receptor Detection Toolkit
por: Hu, Yifei, et al.
Publicado: (2020)

Chimeric antigen receptor T-cell therapy
por: Burge, Cale, et al.
Publicado: (2023)

High affinity FRβ-specific CAR T cells eradicate AML and normal yeloid lineage without HSC toxicity
por: Lynn, Rachel C, et al.
Publicado: (2016)

T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape
por: Dai, Zhenyu, et al.
Publicado: (2022)

Chimeric antigen receptor‐modified human regulatory T cells that constitutively express IL‐10 maintain their phenotype and are potently suppressive
por: Mohseni, Yasmin R., et al.
Publicado: (2021)

Effective chimeric antigen receptor T cells against SARS-CoV-2
por: Guo, Xueyang, et al.
Publicado: (2021)

Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice
por: Hu, Xiaomeng, et al.
Publicado: (2023)

Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
por: Roddie, Claire, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o0uqnh5n9j4upd92t3car602if